

Elekta Announces Resignation of Board Member Kelly Londy

STOCKHOLM – Elekta AB (EKTA-B.ST), a global leader in precision radiation therapy, today announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective today, March 1, 2024.

Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta's Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.

#

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.